Dr. Dutcus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Eisai Inc
200 Metro Boulevard
Nutley, NJ 07110Phone+1 201-699-6709Fax+1 732-791-1188
Summary
- Senior Vice President Clinical Development
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 1999 - 2002
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1996 - 1999
Iuliu Hatieganu University of Medicine and PharmacyClass of 1990
Certifications & Licensure
NJ State Medical License 2002 - 2025
NY State Medical License 1999 - 2012- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of t...Hyun Cheol Chung, Esma Saada-Bouzid, Federico Longo, Eduardo Yanez, Seock-Ah Im
Cancer. 2024-10-01 - 1 citationsLenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.Antonio González-Martín, Hyun Cheol Chung, Esma Saada-Bouzid, Eduardo Yanez, Helene Senellart
Gynecologic Oncology. 2024-07-01 - 7 citationsPembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Random...James Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, Jong-Seok Lee, Piotr Koralewski
Journal of Thoracic Oncology. 2024-06-01
Journal Articles
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
Press Mentions
KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) in Combination with Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients with Unresectable, Non-Metastatic Hepatocellular CarcinomaSeptember 14th, 2024- Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) in Certain Patients with Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)April 7th, 2023
- Merck and Eisai Present Results from Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (Pembrolizumab) plus LENVIMA® (Lenvatinib) Versus LENVIMA Monotherapy in Patients with Unresectable Hepatocellular CarcinomaSeptember 10th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
